Buy & Sell Amgen, Inc. (AMGN) – Amgen, Inc. Price Today
Aura AI Summary
Key Stats
- $190.44BMarket Cap
- HealthSector
- -10.4%3M Drawdown
- $235.92BEnterprise Value
- 2.85%Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 74 daysTypical Hold Time
Amgen, Inc. (AMGN) is currently valued at a market capitalization of $190.44B, with an enterprise value of $235.92B. Over the past 52 weeks, Amgen, Inc. has traded between a low of $262.28 and a high of $388.16, highlighting its annual price range. Over the past three months, Amgen, Inc. has recorded a drawdown of -10.4%, reflecting recent price volatility. Amgen, Inc. offers a dividend yield of 2.85%, with the most recent dividend of $2.52 paid on 13 Feb 26. On average, investors hold Amgen, Inc. for approximately 74 days, indicating typical investor behavior on the platform.
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
